Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Jun;40(6):969-70.
doi: 10.1007/s00259-013-2385-z. Epub 2013 Apr 5.

Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

Sven Norbert Reske, Gordon Winter, Benjamin Baur, Hans-Jürgen Machulla, Thomas Kull
Comment

Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

Sven Norbert Reske et al. Eur J Nucl Med Mol Imaging. 2013 Jun.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a A 70-year-old patient with a history of prostatectomy because of PCa 12 years before the examination, Gleason score 5 + 5, local radiation therapy and castration-resistant PCa at presentation, PSA 3 ng/ml. 11C-choline PET/CT showed large local recurrence and disseminated bone marrow metastases. Completely concordant 68Ga-DOTA-DUPA-Pep findings with disseminated bone marrow metastases confirmed by MRI and a large local recurrence (arrow). Note normal tissue background mostly in blood pool, uptake in kidneys and urinary tract with some urine contamination (arrowhead) due to urinary conduit because of incontinence and very faint uptake in salivary glands. Maximum intensity projection (MIP) of a PET image of the trunk acquired 1 h after injection of 85 MBq 68Ga-DOTA-DUPA-Pep. b A 74-year-old patient with a history of PCa 2 years before the examination, stage II, Gleason score 3 + 3, androgen deprivation therapy with bicalutamide, PSA at presentation 0.2 ng/ml. 68Ga-DOTA-DUPA-Pep PET shows uptake in kidneys, urinary tract and blood pool and faintly in salivary and lacrimal glands. There is no evidence of tumour deposits. Interestingly, also faint uptake is seen due to gynaecomastia (arrowheads). MIP PET as in a, 105 MBq 68Ga-DOTA-DUPA-Pep
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–495. doi: 10.1007/s00259-012-2298-2. - DOI - PubMed
    1. Bařinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19:856–870. doi: 10.2174/092986712799034888. - DOI - PMC - PubMed
    1. Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–697. doi: 10.1021/bc200279b. - DOI - PubMed
    1. Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380–387. doi: 10.2967/jnumed.112.111203. - DOI - PubMed
    1. Winter G, Zlatopolskiy B, Kull T, Bertram J, Genze F, Cudek G, et al. 68Ga-DOTA-DUPA-Pep as a new peptide conjugate for molecular imaging of prostate carcinoma. J Nucl Med. 2011;52(Suppl 1):1597.